ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Carolyn Jean Presley, MD, and James L. Mulshine, MD, on New Lung Cancer CT Screening Guidelines and Treatment Burden

James L. Mulshine, MD, of Rush University Medical Center, and Carolyn Jean Presley, MD, of Yale Cancer Center/Yale School of Medicine, discuss the burden on patients and the Medicare system as new lung cancer CT guidelines are put into effect and treatment of early-stage NSCLC increases (Abstract 7533).

Supportive Care

Symptom Management

Palliative Care

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

Daniel A. Vorobiof, MD, of the Sandton Oncology Centre, and Bernardo Leon Rapoport, MD, of The Medical Oncology Centre of Rosebank, discuss the first study to evaluate the efficacy and safety of a single dose of intravenous fosaprepitant. The use of this NK1 inhibitor and another (rolapitant) in a second study discussed may change the management of chemotherapy-induced nausea and vomiting and improve quality of life for patients (Abstracts 9629 and 9615).

Prostate Cancer

Howard I. Scher, MD

Howard I. Scher, MD, on the Prostate Cancer Working Group 3 Consensus

Howard I. Scher, MD, of Memorial Sloan Kettering Cancer Center, discusses the updated criteria that will guide clinical trial design and conduct for therapeutics being tested in castration-resistant prostate cancer (Abstract 5000).

Colorectal Cancer

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD, on HERACLES and Other Colorectal Cancer Findings

Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, and Axel Grothey, MD, of the Mayo Clinic, discuss the Italian-led study on trastuzumab and lapatinib in HER2-amplified metastatic colorectal as well as other colorectal cancer findings discussed at ASCO (Abstract 3508).

Breast Cancer

Nicholas C. Turner, MD, PhD

Nicholas C. Turner, MD, PhD, Summarizes Results of the PALOMA3 Breast Cancer Study

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital NHS Trust, discusses fulvestrant and palbociclib as a treatment option in pre- and postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy (Abstract LBA502).

Aug

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Carolyn Jean Presley, MD, and James L. Mulshine, MD, on New Lung Cancer CT Screening Guidelines and Treatment Burden

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

Howard I. Scher, MD, on the Prostate Cancer Working Group 3 Consensus

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD, on HERACLES and Other Colorectal Cancer Findings

Nicholas C. Turner, MD, PhD, Summarizes Results of the PALOMA3 Breast Cancer Study

Metabolic Syndrome Frequently Documented During First Year of ADT-ARPI Therapy in Prostate Cancer

The Mid-Career Oncologist in LMIC Regions: Navigating Disparities, Avoiding Burnout, and Delivering Optimal Care

Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds

Preoperative Weight-Loss Program Shows Feasibility Before Endometrial Cancer Surgery

ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases